An external third party (pharma partner) will be the validation the market needs and could be seen as a measure of the strength of the AA chances from their perspective IMO .... who that partner / global pharma is and for what amount they contribute will be telling (again IMO) ....
..... chances are they have seen more Rexlemestrocel-L data through an NDA than the 'docs' on HC have (lol) so the size of their financial commitment will IMO be a measure / guidance as to their confidence in a successful FDA AA outcome for this indication ?
GLTAH
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-122
-
- There are more pages in this discussion • 428 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |